An observational study in HIV -1 Infection, Antiretroviral Therapy and Drug Resistance, Microbial, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Chinese University of Hong Kong · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in HIV Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. HIV Infections · China.
Among the 67 studies in HIV Infections with a site in China, this one is the 9th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2025, is one of 16 observational ones, and was the 65th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →10 of the 67 studies in HIV Infections with a site in China are open now. Recruiting first, the newest first:
Liaoning Chengda Biotechnology CO., LTD · Sites in China
Ages 18–60
Jecho Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18–65
Shanghai Public Health Clinical Center · Sites in China
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18+
Affiliated Hospital of Guangdong Medical University · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 5 · Phase 3 11 · Phase 4 14
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 420 is above the median of 200 across 781 observational studies indexed under HIV Infections.
Median enrollment 145 across the 50 interventional studies, 435 across the 16 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 67 have an industry lead sponsor. The 10 most frequent:
Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Chinese University of Hong Kong has 8 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in HIV Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06830668National Center for AIDS/STD Control and Prevention, China CDCSame-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation | 2026-12-31 |
| NCT07579741Jecho Biopharmaceuticals Co., Ltd.A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders | 2027-02-12 |
| NCT07932132Liaoning Chengda Biotechnology CO., LTDImmunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 67 studies in HIV Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to determine the prevalence of drug resistance mutation (DRM) in virally suppressed HIV infection, and the impacts of regimen change and the presence of low level viremia. Adults living with HIV infection on antiretroviral therapy (ART) with full viral suppression would be recruited. Cases are patients planning for regimen switch, while controls are those with and without low level viraemia (LLV) not planned for switch. Blood samples would be collected before and after switch. Sequencing would be performed to identify DRM present in HIV-1 proviral DNA.
Aim/objectives: With the aim of determining the impact of antiretroviral regimen and switch on archived HIV-1 drug resistance mutation (DRM), the study's objectives are, to: (a) estimate the prevalence of DRM in virally suppressed HIV infection; (b) assess changes in archived resistance before and after switch; and (c) identify predictors of archived DRM after regimen switch.
Design: A prospective observational study
Setting: All HIV specialist clinic services in Hong Kong
Methods: Adults living with HIV infection on antiretroviral therapy (ART) with full viral suppression who are planned for regimen switch would be recruited. Controls are patients with and without low level viraemia (LLV) not planned for switch, matched by antiretroviral regimen. Blood samples would be collected before switch, shortly and then 2-3 years after switch. Nanopore sequencing would be performed to identify DRM present in HIV-1 proviral DNA. Transcription of relevant clinical record data would be made to contribute to statistical and phylogenetic analyses
Main outcome measures: Change in DRM frequency between baseline and followups at (a) short term and long term; (b) occurrence of virological failure and time to failure; (c) difference in DRM frequency between presence and absence of LLV, and switched and non-switched patients.
Anticipated outcome: The study results would determine if archived resistance clearance would change following ART switch, identify factors associated with persistence of archived resistance, and inform management on the application of proviral DNA testing in clinical practice.
Patients living with HIV and who are attendees of HIV specialist clinics in the public service in Hong Kong
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
virally suppressed with viral undetectable at 2 consecutive timepoints prior to enrolment
with and without low level viraemia prior to enrolment
Proportional difference of drug resistance mutation at short term after regimen switch
Percentage difference between the prevalence of drug resistance mutation (DRM) detected by proviral DNA testing at baseline and short term (3-6 months) after regimen switch
Time frame: from enrolment to 3-6 months
Proportional difference of drug resistance mutation at long term after regimen switch
Percentage difference between the prevalence of drug resistance mutation (DRM) detected by proviral DNA testing at baseline and long term (2-3 years) after regimen switch
Time frame: From enrolment to 2-3 years after regimen switch
Prevalence of drug resistance mutation
Percentage of patients on antiretroviral therapy with drug resistance mutation (DRM) detected by proviral DNA testing at baseline
Time frame: at enrolment
Proportional Difference of drug resistance mutation prevalence between patients with and without by low level viremia
Percentage difference in the prevalence of drug resistance mutation (DRM) detected by proviral DNA testing between the presence and absence of low level viremia at baseline
Time frame: at enrolment
Prevalence of virologic failure
Prevalence of virologic failure in patients on antiretroviral therapy at 2-3 years after enrolment
Time frame: From enrolment to 2-3 years
Plan to share: No — Individual data are protected as per provision of the approval of the Ethics Committee
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Sep 2029, 47 months after the start.
Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 47 months is above that.
Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →